Multiple Sclerosis Trial, Recruiting NCT07011914 Sponsor: NYU Langone Health Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT07011914
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For Part 1 of the study (Aim 1):

  • People aged 18 to 29 years old
  • People who have been diagnosed with relapsing-remitting multiple sclerosis (a form of MS with flare-ups and periods of recovery)
  • At least 70% of participants in this part will be people who identify as Black, Hispanic, or who have a low household income (at or below 138% of the federal poverty level)
  • People who speak English or Spanish fluently

For Part 2 of the study (Aim 2):

  • People aged 18 to 29 years old
  • People who have been diagnosed with relapsing-remitting multiple sclerosis
  • At least 70% of participants in this part will be people who identify as Black, Hispanic, or who have a low household income
  • People who can read English or Spanish
  • People whose MS either started before age 18 (and who are between 18–25 at the time of joining), or people whose MS started at age 18 or older (and who are between 19–29 at the time of joining)
  • People who have had MS for less than 8 years

For Part 3 of the study (Aim 3):

  • The first 20 people from Part 2 who completed at least 80% of the Part 2 study data
  • At least 70% of participants in this part will be people who identify as Black, Hispanic, or who have a low household income
  • Participants will be selected based on their scores on a general health and wellbeing questionnaire, with an even split between those with the highest and lowest scores (confirm with trial site)

Who may not be able to join:

  • People who have primary progressive MS or secondary progressive MS (forms of MS that worsen more steadily without clear flare-ups)
  • People who are not able to give their own informed consent to take part
  • People who have had an MS relapse (a flare-up of symptoms) within the 30 days before joining the study
  • People who have another significant neurological or psychiatric condition

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Lauren Krupp, MD, NYU Langone Health

Phone: 646-501-7528

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
23 October 2025
Est. completion
30 June 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Severity of MS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov